Qosina Introduces New Genderless AseptiQuik ® W Series Connectors for Large-Volume, High-Flow Production Environments

Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to introduce CPC’s (Colder Products Company) new AseptiQuik® W Series connectors to its extensive line of aseptic genderless connectors.

The new genderless AseptiQuik ® W Series connectors, with a 1 1/2” flow path, enable quick and easy sterile connections in large-volume, high-flow production and process intensification environments. The large diameter connection allows for higher flow rates, reducing the risk of flow restrictions or pressure drops that could negatively impact process performance.

The genderless design of the AseptiQuik® simplifies system integration and minimizes the risk of operator error. The connectors’ robust construction provides reliable performance without the need for clamps or fixtures. Biopharmaceutical manufacturers benefit from interchangeable 1”, 1 ¼” and 1 ½” flow solutions for full-scale bioprocessing production environments.

The AseptiQuik® W Series body is made of polycarbonate and is available in a high temperature (HT) version, suitable for autoclave or gamma irradiation applications.

Part numbers:

  • AQW17016HT – AseptiQuik® W Sterile Connector, High Temperature, Fits 1 inch ID Tubing
    (25.4 mm)
  • AQW17020HT – AseptiQuik® W Sterile Connector, High Temperature, Fits 1 1/4 inch ID Tubing
    (1.25 inch, 31.75 mm)
  • AQW17024HT – AseptiQuik® W Sterile Connector, High Temperature, Fits 1 1/2 inch ID Tubing
    (1.5 inch, 38.1 mm)
  • AQW33024HT – AseptiQuik® W Sterile Connector, High Temperature, 1 1/2 inch Sanitary Flange

Learn more about Qosina’s new line of AseptiQuik® W Series connectors.

Qosina is a one-stop source for single-use bioprocess components, with low minimum orders, a liberal sampling policy and bill of material kitting, all supported by regulatory documentation and backed by Qosina’s assurance of supply.

Explore Qosina’s full line of aseptic genderless connectors at www.qosina.com/aseptic-connectors.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”